免疫调节治疗不增加有结肠外癌病史的炎症性肠病患者癌症风险
该研究基于ENEIDA登记数据库,回顾性分析520例有结肠外癌病史且此前未用过免疫抑制治疗的炎症性肠病患者,比较后续使用免疫抑制治疗(IMT;硫嘌呤类、抗肿瘤坏死因子药物)与未使用者的新发癌症(复发或新发)情况。结果示暴露组与未暴露组新发癌症比例相似(16% vs 18%,P=0.53),无癌生存率在1、2、5年分别为暴露组99%、98%、97%,未暴露组97%、96%、92%(P=0.03)。结论认为在有癌症病史的IBD患者中,使用IMT不增加新发或复发癌症风险,即使早期启用。
要点
- 有结肠外癌病史的IBD患者中,使用免疫抑制治疗(IMT)者与未使用者新发癌症比例相似(16% vs 18%,P=0.53)。
- 无癌生存率暴露组1、2、5年分别为99%、98%、97%,未暴露组为97%、96%、92%(P=0.03)。
- 仅纳入癌症诊断后5年内启用IMT者,两组新发癌症率无差异。
核心结论
- 在有与免疫抑制无关的癌症病史的IBD患者中,使用IMT不增加新发或复发癌症风险,即使癌症诊断后早期启用IMT亦如此。
研究设计与样本
- 基于ENEIDA登记数据库的回顾性研究,纳入520例有结肠外癌病史且癌症诊断前未使用过IMT的IBD患者。
- 其中146例后续接受IMT治疗(暴露组),374例未接受(非暴露组),采用log-rank检验进行比较。
主要发现
- 暴露组新发癌症比例为16%,非暴露组为18%(P=0.53)。
- 暴露组无癌生存率在1、2、5年分别为99%、98%、97%,非暴露组分别为97%、96%、92%(P=0.03)。
- 两组索引癌症诊断时年龄相差超过10年。
- 仅纳入癌症诊断后5年内启用IMT者时,暴露组与非暴露组新发癌症率无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses the impact of the use of IMTs on the development of incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) and a history of malignancy. METHODS: Patients with IBD included in the ENEIDA registry with a history of cancer without being exposed to IMTs were identified and retrospectively reviewed and compared regarding further treatment with IMTs or not by means of a log-rank test. RESULTS: Overall, 520 patients with previous extracolonic cancer naive to IMTs before the diagnosis of cancer were identified. Of these, 146 were subsequently treated with IMTs (exposed), whereas 374 were not (nonexposed). The proportion of patients with incident cancers was similar in both exposed (16%) and nonexposed (18%) patients (P = 0.53); however, there was more than a 10-year difference in the age at index cancer between these 2 groups. Cancer-free survival was 99%, 98%, and 97% at 1, 2, and 5 years in exposed patients, and 97%, 96%, and 92% at 1, 2, and 5 years in non-exposed patients, respectively (P = 0.03). No differences in incident cancer rates were observed between exposed and nonexposed patients when including only those who were exposed within the first 5 years after cancer diagnosis. DISCUSSION: In patients with IBD and a history of cancer not related to immunosuppression, the use of IMTs is not associated with an increased risk of new or recurrent cancers even when IMTs are started early after cancer diagnosis.
引用
- Mañosa M, Chaparro M, Juan A, et al. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol. 2019. PMID: 31082839. doi:10.14309/ajg.0000000000000210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。